The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
NLRP3 inflammasome activation drives tau pathology
Open accessAbstract
Alzheimer’s disease is characterized by the accumulation of amyloid-beta in plaques, aggregation of hyperphosphorylated tau in neurofibrillary tangles and neuroinflammation, together resulting in neurodegeneration and cognitive decline1. The NLRP3 inflammasome assembles inside of microglia on activation, leading to increased cleavage and activity of caspase-1 and downstream interleukin-1β release2. Although the NLRP3 inflammasome has been shown to be essential for the development and progression of amyloid-beta pathology in mice3, the precise effect on tau pathology remains unknown. Here we show that loss of NLRP3 inflammasome function reduced tau hyperphosphorylation and aggregation by regulating tau kinases and phosphatases. Tau activated the NLRP3 inflammasome and intracerebral injection of fibrillar amyloid-beta-containing brain homogenates induced tau pathology in an NLRP3-dependent manner. These data identify an important role of microglia and NLRP3 inflammasome activation in the pathogenesis of tauopathies and support the amyloid-cascade hypothesis in Alzheimer’s disease, demonstrating that neurofibrillary tangles develop downstream of amyloid-beta-induced microglial activation. The authors show that NLRP3 inflammasome is activated in microglia of patients with fronto-temporal dementia and in a mouse model of tau pathology, and that the loss of NLRP3 inflammasome function decreases tau pathology and improves cognition in mice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The NLRP3-ASC inflammasome mechanisms contributing to increased beta-amyloids and tau are thought to be a combination of kinases and phosphatases involved in tau phosphorylation [96] through the production of IL-1 beta.”
From The Role of Cortisol in Chronic Stress, Neurodegenerative Diseases, and Psychological Disorders (2023) · cites this paper as [96]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the CNS, inflammasome activation has been mainly linked to neuroinflammatory conditions. As example, it has an essential role in the progression of several neurological disorders like MS, AD, PPD, and NPS (132, 193–197).”
From The gut-brain axis: how microbiota and host inflammasome influence brain physiology and pathology (2020) · cites this paper as [197]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In particular, microglial NLRP3 has been shown to be a major driver of amyloid beta and tau toxicity in AD, suggesting its activation has important implications for disease progression (Halle et al, 2008; Venegas et al, 2017; Ising et al, 2019).”
From Mechanisms of DNA damage-mediated neurotoxicity in neurodegenerative disease (2022) · cites this paper as Ising et al, 2019
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The activation of hippocampal NLRP3 inflammasome-mediated pyroptosis is associated with neuronal damage, cognitive decline, and neuronal death (Hanslik & Ulland, 2020; Heneka et al., 2013; Ising et al., 2019; Venegas et al., 2017).”
From Picroside II Alleviates the Progression of Alzheimer’s Disease via the NLRP3/Caspase-1/GSDMD Pathway (2025) · cites this paper as Ising et al., 2019
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“On the other hand, treatment of mouse primary hippocampal neurons with conditioned media from wild-type, but not Nlrp3−/− and Asc−/−, microglia primed with LPS resulted in elevated total and phosphorylated tau levels, suggesting that NLRP3 inflammasome activation in microglia can induce tau pathology in neurons.”
From Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease (2023) · cites this paper as [81]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Additionally, several cytokines, including IL-1β and IL-6, can directly induce tau phosphorylation in vitro, thus potentially contributing to the development of tau pathology.54”
From Amelioration of Tau and ApoE4-linked glial lipid accumulation and neurodegeneration with an LXR agonist (2024) · cites this paper as [56]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Research by Ising et al. suggests that tau proteins can activate the NLRP3 inflammasome, which then promotes excessive tau phosphorylation and aggregation by affecting specific tau kinases and phosphatases.252”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [252]
The cited source says what the claim attributes to it.
In the citing paper
“In turn, the NLRP3 inflammasome is essential for the development and progression of Aβ pathology in mice29 and may drive tau pathology through Aβ-induced microglial activation30.”
From New insights into the genetic etiology of Alzheimer’s disease and related dementias (2022) · cites this paper as [30]
The cited source says what the claim attributes to it.
In the citing paper
“A recent study shows that NLR family pyrin domain-containing protein 3 (NLRP3) inflammasome activation induces tau hyperphosphorylation and aggregation through modulating tau kinases and phosphatases [159].”
From Tau and neuroinflammation in Alzheimer’s disease: interplay mechanisms and clinical translation (2023) · cites this paper as [159]
The cited source says what the claim attributes to it.
In the citing paper
“On the other hand, microglia could also drive tau spreading and toxicity by promoting neuroinflammation, such as activating NACHT-, LRR- and pyrin (PYD)-domain-containing protein 3 (NLRP3) inflammasome155 or inducing NF-kB signaling.”
From Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets (2023) · cites this paper as [155]
The cited source says what the claim attributes to it.
In the citing paper
“Tau oligomers and monomers can also activate NLRP3 inflammasomes, further perpetuating microglial activation [162] and potential progression of tau pathology.”
From Microglia and monocytes in inflammatory CNS disease: integrating phenotype and function (2022) · cites this paper as [162]
The cited source says what the claim attributes to it.
In the citing paper
“Treatment of wild-type primary microglia with recombinant wild-type tau and recombinant tau with a P301S mutation increased IL-1β secretion, an effect that was attenuated in Nlrp3−/− and Asc−/− microglia, suggesting that tau induces IL-1β secretion in a NLRP3-dependent manner [81].”
From Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease (2023) · cites this paper as [81]
The cited source says what the claim attributes to it.
In the citing paper
“Inhibiting or downregulating the NLRP3 inflammasome ameliorates AD neuropathology in animal models, which opens up a therapeutic avenue for modulators of NLRP3 activation in AD.”
From Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease (2023) · cites this paper as [81]
The cited source says what the claim attributes to it.
In the citing paper
“On the other hand, treatment of mouse primary hippocampal neurons with conditioned media from wild-type, but not Nlrp3−/− and Asc−/−, microglia primed with LPS resulted in elevated total and phosphorylated tau levels, suggesting that NLRP3 inflammasome activation in microglia can induce tau pathology in neurons.”
From Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease (2023) · cites this paper as [81]
The cited source says what the claim attributes to it.
In the citing paper
“Treatment of wild-type primary microglia with recombinant wild-type tau and recombinant tau with a P301S mutation increased IL-1β secretion, an effect that was attenuated in Nlrp3−/− and Asc−/− microglia, suggesting that tau induces IL-1β secretion in a NLRP3-dependent manner [81].”
From Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease (2023) · cites this paper as [81]
The cited source says what the claim attributes to it.
In the citing paper
“The NLRP3 inflammasome has a bidirectional relationship with AD-related tau pathology as well.”
From Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease (2023) · cites this paper as [81]
The cited source says what the claim attributes to it.
In the citing paper
“Evidence suggests that while some forms of tau can activate the NLRP3 inflammasome, inflammasome activation can exacerbate tau pathology by promoting elevated phosphorylation of tau [81, 82].”
From Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease (2023) · cites this paper as [81]
The cited source says what the claim attributes to it.
In the citing paper
“Moreover, treatment with brain homogenates from APP/PS1 mice induced tau hyperphosphorylation in a mouse model of tau aggregation pathology (Tau22) but not in Tau22/Nlrp3−/− and Tau22/Asc−/− mice, indicating the NLRP3 inflammasome as a mediator of Aβ-induced tau pathology [81].”
From Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease (2023) · cites this paper as [81]
The cited source says what the claim attributes to it.
In the citing paper
“Moreover, treatment with brain homogenates from APP/PS1 mice induced tau hyperphosphorylation in a mouse model of tau aggregation pathology (Tau22) but not in Tau22/Nlrp3−/− and Tau22/Asc−/− mice, indicating the NLRP3 inflammasome as a mediator of Aβ-induced tau pathology [81].”
From Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease (2023) · cites this paper as [81]
The cited source says what the claim attributes to it.
In the citing paper
“Evidence suggests that while some forms of tau can activate the NLRP3 inflammasome, inflammasome activation can exacerbate tau pathology by promoting elevated phosphorylation of tau [81, 82].”
From Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease (2023) · cites this paper as [81]
The cited source says what the claim attributes to it.
In the citing paper
“In Tau22 mice, ablation of Nlrp3 or Asc reduced levels of hyperphosphorylated tau and tau aggregates and rescued tau-induced spatial memory deficits [81].”
From Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease (2023) · cites this paper as [81]
In the citing paper
“Studies have demonstrated important roles of the NLRP3 inflammasome in aging and age-related diseases, such as atherosclerosis metabolic syndrome, type 2 diabetes, and Alzheimer’s disease (81–83).”
From Connecting aging biology and inflammation in the omics era (2022) · cites this paper as [83]
In the citing paper
“For example, in AD and frontotemporal dementia, neuroinflammation and microglia activation potentiate the spreading of pathological tau neurofibrillary tangles (83, 175).”
From Connecting aging biology and inflammation in the omics era (2022) · cites this paper as [83]
In the citing paper
“In AD, this relationship may be mediated by NLRP3 inflammasome activation in microglia, a process that activates tau kinases (e.g., GSK-3β and CaMKII-α) and results in tau hyperphosphorylation (83).”
From Connecting aging biology and inflammation in the omics era (2022) · cites this paper as [83]
In the citing paper
“The knockout of ASC or NLRP3 ameliorates AD‐like brain pathology in animal models. 68”
From Senescence, brain inflammation, and oligomeric tau drive cognitive decline in Alzheimer's disease: Evidence from clinical and preclinical studies (2024) · cites this paper as [68]
In the citing paper
“The activation of the NLRP3 inflammasome drives tau pathology. 68”
From Senescence, brain inflammation, and oligomeric tau drive cognitive decline in Alzheimer's disease: Evidence from clinical and preclinical studies (2024) · cites this paper as [68]
In the citing paper
“Inflammaging can drive tau pathology and neurodegeneration in AD by impairing the clearance of Aβ peptides, altering BBB integrity, and affecting the synaptic functions. 68”
From Senescence, brain inflammation, and oligomeric tau drive cognitive decline in Alzheimer's disease: Evidence from clinical and preclinical studies (2024) · cites this paper as [68]
In the citing paper
“In general, patients affected by tauopathies showed elevated levels of cleaved caspase-1 and ASC and mature IL-1β in the cortex (197).”
From The gut-brain axis: how microbiota and host inflammasome influence brain physiology and pathology (2020) · cites this paper as [197]
In the citing paper
“Injecting brain homogenates from APP/PS1 or wild-type mice into the hippocampus of Tau22 mice, induced tau hyperphosphorylation in the hippocampus of Tau22 wild-type but not Tau22/Pycard−/− or Tau22/Nlrp3−/− deficient mice”
From The gut-brain axis: how microbiota and host inflammasome influence brain physiology and pathology (2020) · cites this paper as [197]
In the citing paper
“suggesting that NLRP3 activation is upstream the Aβ-tau cascade and tau pathology (197).”
From The gut-brain axis: how microbiota and host inflammasome influence brain physiology and pathology (2020) · cites this paper as [197]
In the citing paper
“Consistent with this, Tau22 mice lacking ASC or NLRP3 expression had lower levels of aggregated and hyperphosphorylated tau in the hippocampus, and their typical spatial memory deficits were rescued (197).”
From The gut-brain axis: how microbiota and host inflammasome influence brain physiology and pathology (2020) · cites this paper as [197]
In the citing paper
“Also, Tau22 mice, another model of AD and other tauopathies, had increased levels of cleaved caspase-1 and ASC in their brain at the age of 11 months compared to their 3-month-old counterparts.”
From The gut-brain axis: how microbiota and host inflammasome influence brain physiology and pathology (2020) · cites this paper as [197]
In the citing paper
“Further, activated microglia promote tau phosphorylation and aggregation by activation of the NLRP3 (nucleotide binding oligomerisation domain (NOD)-, leucine-rich repeat (LRR)- and pyrin domain-containing protein 3) inflammasome in response to amyloid-β [22,23].”
From ROS Generation in Microglia: Understanding Oxidative Stress and Inflammation in Neurodegenerative Disease (2020) · cites this paper as [23]
In the citing paper
“Further, there is evidence tauopathy is driven by NLRP3 inflammasome activation in microglia in response to amyloid-β [23].”
From ROS Generation in Microglia: Understanding Oxidative Stress and Inflammation in Neurodegenerative Disease (2020) · cites this paper as [23]
In the citing paper
“ROS from NOX4 also contribute to activation of the NLRP3 inflammasome, a driver of both amyloid-β [156] and tau [23] pathology.”
From ROS Generation in Microglia: Understanding Oxidative Stress and Inflammation in Neurodegenerative Disease (2020) · cites this paper as [23]
In the citing paper
“Growing evidence indicates that Aβ accumulation stimulates tau phosphorylation and fibrillary tangle formation, leading to the process of neurodegeneration.112–114”
From Amyloid β-based therapy for Alzheimer’s disease: Challenges, successes and future (2023) · cites this paper as [112]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Szklarczyk, D., Morris, J. H., Cook, H., Kuhn, M., Wyder, S., Simonovic, M., Santos, A., Doncheva, N. T., Roth, A., Bork, P., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw937 · Cited by 6,980
NLRP3 is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice
Heneka, M. T., Kummer, M. P., Stutz, A., Delekate, A., Schwartz, S., Vieira-Saecker, A., Griep, A., Axt, D., Remus, A., Tzeng, T.-C., et al. (2013) · Nature · doi:10.1038/nature11729 · Cited by 2,898
Self-citationThe NALP3 inflammasome is involved in the innate immune response to amyloid-β
Halle, A., Hornung, V., Petzold, G. C., Stewart, C. R., Monks, B. G., Reinheckel, T., Fitzgerald, K. A., Latz, E., Moore, K. J., & Golenbock, D. T. (2008) · Nature Immunology · doi:10.1038/ni.1636 · Cited by 2,441
Self-citationDepletion of microglia and inhibition of exosome synthesis halt tau propagation
Asai, H., Ikezu, S., Tsunoda, S., Medalla, M., Luebke, J., Haydar, T., Wolozin, B., Butovsky, O., Kügler, S., & Ikezu, T. (2015) · Nature Neuroscience · doi:10.1038/nn.4132 · Cited by 1,591
Formation of Neurofibrillary Tangles in P301L Tau Transgenic Mice Induced by Aβ42 Fibrils
Götz, J., Chen, F., van Dorpe, J., & Nitsch, R. M. (2001) · Science · doi:10.1126/science.1062097 · Cited by 1,526
Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3
Kanneganti, T., Özören, N., Body–Malapel, M., Amer, A. O., Park, J., Franchi, L., Whitfield, J. R., Barchet, W., Colonna, M., Vandenabeele, P., et al. (2006) · Nature · doi:10.1038/nature04517 · Cited by 1,149
Tau pathology in Alzheimer disease and other tauopathies
Iqbal, K., del C. Alonso, A., Chen, S., Chohan, M. O., El-Akkad, E., Gong, C.-X., Khatoon, S., Li, B., Liu, F., Rahman, A., et al. (2005) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2004.09.008 · Cited by 1,037
Microglia-derived ASC specks cross-seed amyloid-β in Alzheimer’s disease
Venegas, C., Kumar, S., Franklin, B. S., Dierkes, T., Brinkschulte, R., Tejera, D., Vieira-Saecker, A., Schwartz, S., Santarelli, F., Kummer, M. P., et al. (2017) · Nature · doi:10.1038/nature25158 · Cited by 983
Self-citationInflammasome signalling in brain function and neurodegenerative disease
Heneka, M. T., McManus, R. M., & Latz, E. (2018) · Nature Reviews Neuroscience · doi:10.1038/s41583-018-0055-7 · Cited by 836
Self-citationCanonical Nlrp3 Inflammasome Links Systemic Low-Grade Inflammation to Functional Decline in Aging
Youm, Y.-H., Grant, R. W., McCabe, L. R., Albarado, D. C., Nguyen, K. Y., Ravussin, A., Pistell, P., Newman, S., Carter, R., Laque, A., et al. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.09.010 · Cited by 674
Cited by
Sorted by citations
Items 301–400 of 1,003
Zhang, L., Liu, X., Liu, D., Yu, X., Zhang, L. L., Zhu, J., Lü, S., & Liu, R. (2020) · Advanced Functional Materials · doi:10.1002/adfm.201910691 · Cited by 54
The role of glia in protein aggregation
Li, Q., & Haney, M. S. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105015 · Cited by 54
Cytokine signaling convergence regulates the microglial state transition in Alzheimer’s disease
Lau, S., Fu, A. K. Y., & Ip, N. Y. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-03810-0 · Cited by 55
BAD-mediated neuronal apoptosis and neuroinflammation contribute to Alzheimer's disease pathology
Zhang, L., Qian, Y., Li, J., Zhou, X., Xu, H. J., Yan, J., Xiang, J., Yuan, X., Sun, B., Sisodia, S. S., et al. (2021) · iScience · doi:10.1016/j.isci.2021.102942 · Cited by 54
León, B. E., Kang, S., Franca-Solomon, G., Shang, P., & Choi, D. (2022) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2021.778456 · Cited by 56
TRIM family proteins: roles in proteostasis and neurodegenerative diseases
Zhu, Y., Afolabi, L. O., Wan, X., Shim, J. S., & Chen, L. (2022) · Open Biology · doi:10.1098/rsob.220098 · Cited by 55
Association of Glial Activation and α-Synuclein Pathology in Parkinson’s Disease
Wang, R., Ren, H., Kaznacheyeva, E. V., Lu, X., & Wang, G. (2022) · Neuroscience Bulletin · doi:10.1007/s12264-022-00957-z · Cited by 51
Xu, Z., Zhou, X., Xiao, H., Wang, S., Wei, J., Huang, J., Ji, L., Yang, Y., Efferth, T., Hong, C., et al. (2023) · Phytomedicine · doi:10.1016/j.phymed.2023.154695 · Cited by 51
Microglial TLR4/NLRP3 Inflammasome Signaling in Alzheimer’s Disease
Li, Y., Chen, X., Zhou, M., Feng, S., Peng, X., & Wang, Y. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230273 · Cited by 58
Rossano, S. M., Johnson, A. S., Smith, A. P., Ziaggi, G., Roetman, A. E., Guzman, D., Okafor, A., Klein, J., Tomljanovic, Z., Stern, Y., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13699 · Cited by 54
Tau induces inflammasome activation and microgliosis through acetylating NLRP3
Zhang, L., Gai, Y., Liu, Y., Meng, D., Zeng, Y., Luo, Y., Zhang, H., Wang, Z., Yang, M., Li, Y., et al. (2024) · Clinical and Translational Medicine · doi:10.1002/ctm2.1623 · Cited by 52
Glial AP1 is activated with aging and accelerated by traumatic brain injury
Byrns, C. N., Saikumar, J., & Bonini, N. M. (2021) · Nature Aging · doi:10.1038/s43587-021-00072-0 · Cited by 50
Liu, Q., Zhang, M., Guo, M.-X., Zhang, Q., Li, N.-Z., Cheng, J., Wang, S.-L., Xu, G., Li, C., Zhu, J., et al. (2022) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-021-10037-0 · Cited by 51
Inflammasome Activation in Parkinson’s Disease
Jewell, S. L., Herath, A. M., & Gordon, R. (2022) · Journal of Parkinson s Disease · doi:10.3233/jpd-223338 · Cited by 53
Tipping points in neurodegeneration
Simons, M., Levin, J., & Dichgans, M. (2023) · Neuron · doi:10.1016/j.neuron.2023.05.031 · Cited by 52
P2X7-deficiency improves plasticity and cognitive abilities in a mouse model of Tauopathy
Carvalho, K., Martin, E., Cès, A., Sarrazin, N., Lagouge-Roussey, P., Nous, C., Boucherit, L., Youssef, I., Prigent, A., Faivre, É., et al. (2021) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2021.102139 · Cited by 54
Self-citationDolatshahi, M., Sabahi, M., & Aarabi, M. H. (2021) · Molecular Neurobiology · doi:10.1007/s12035-020-02236-2 · Cited by 51
Zhang, T., Ding, S., & Wang, R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910866 · Cited by 53
Effect of APOE alleles on the glial transcriptome in normal aging and Alzheimer’s disease
Serrano-Pozo, A., Li, Z., Noori, A., Nguyen, H. N., Mezlini, A., Li, L., Hudry, E., Jackson, R. J., Hyman, B. T., & Das, S. (2021) · Nature Aging · doi:10.1038/s43587-021-00123-6 · Cited by 49
Hyperuricemia, Gout, and the Brain—an Update
Latourte, A., Dumurgier, J., Paquet, C., & Richette, P. (2021) · Current Rheumatology Reports · doi:10.1007/s11926-021-01050-6 · Cited by 49
Huang, P., Zhang, L., Tan, Y., & Chen, S. (2023) · Translational Neurodegeneration · doi:10.1186/s40035-023-00337-1 · Cited by 54
Novel insights into RIPK1 as a promising target for future Alzheimer’s disease treatment
Li, S., Qu, L., Wang, X., & Kong, L. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107979 · Cited by 51
Acylated Ghrelin as a Multi-Targeted Therapy for Alzheimer's and Parkinson's Disease
Reich, N., & Hölscher, C. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.614828 · Cited by 48
“Over time, prolonged neuroinflammation encourages various other secondary complications, such as impairments in protein degradation, amyloid misfolding, Tau hyperphosphorylation (in conjunction with the inflammationperpetuating activation of the inflammasome), permeabilization of the BBB, peripheral immune cell infilt…”
BackgroundMcFarland, K. N., & Chakrabarty, P. (2022) · Neurotherapeutics · doi:10.1007/s13311-021-01179-3 · Cited by 48
Liu, X., Ye, M., & Ma, L. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.1022821 · Cited by 51
Zhang, L. L., Hou, S., Movahedi, F., Li, Z., Li, L., Hu, J., Jia, Y., Huang, Y., Zhu, J., Sun, X., et al. (2023) · Nano Today · doi:10.1016/j.nantod.2023.101788 · Cited by 50
Biomaterials-based anti-inflammatory treatment strategies for Alzheimer’s disease
Chu, J., Zhang, W., Liu, Y., Gong, B., Ji, W., Yin, T., Gao, C., Liangwen, D., Hao, M., Chen, C., et al. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.374137 · Cited by 48
Ibrahim, W. W., Skalicka‐Woźniak, K., Budzyńska, B., & Sayed, N. S. E. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110239 · Cited by 47
Fronza, M. G., Alves, D. A. C., Praticò, D., & Savegnago, L. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102033 · Cited by 47
Microglia and gut microbiota: A double-edged sword in Alzheimer's disease
Bano, N., Khan, S., Ahamad, S., Kanshana, J. S., Dar, N. J., Khan, S. J., Nazir, A., & Bhat, S. A. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102515 · Cited by 50
Discovery of DFV890, a Potent Sulfonimidamide-Containing NLRP3 Inflammasome Inhibitor
Shen, D.-M., Byth, K. F., Bertheloot, D., Braams, S., Bradley, S., Dean, D. C., Dekker, C., El‐Kattan, A. F., Franchi, L., Glick, G. D., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02759 · Cited by 50
Self-citationJohnson, N. R., Yuan, P., Castillo, E., Lopez, T. P., Yue, W., Bond, A., Rivera, B. M., Sullivan, M. C., Hirouchi, M., Giles, K., et al. (2023) · Nature Communications · doi:10.1038/s41467-022-35753-w · Cited by 46
Aβ and Tau Regulate Microglia Metabolism via Exosomes in Alzheimer’s Disease
Zhao, Y., Liu, B., Wang, J., Xu, L., Yu, S., Fu, J., Yan, X., & Su, J. (2022) · Biomedicines · doi:10.3390/biomedicines10081800 · Cited by 48
Liu, J., Zhang, X., & Wang, H. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113680 · Cited by 46
Mechanistic and therapeutic role of NLRP3 inflammasome in the pathogenesis of Alzheimer's disease
Jha, D., Bakker, E. N. T. P., & Kumar, R. K. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.15788 · Cited by 48
Xu, L., Zhu, J., Rong, L., Yang, H., Wang, B., Lü, S., Zhang, L. L., Li, F., Yang, S., Wang, Z., et al. (2024) · Theranostics · doi:10.7150/thno.95423 · Cited by 46
Lista, S., Munafò, A., Caraci, F., Imbimbo, C., Emanuele, E., Minoretti, P., Pinto-Fraga, J., Merino-País, M., Crespo‐Escobar, P., López‐Ortiz, S., et al. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102659 · Cited by 50
Control of Innate Immunity by Sialic Acids in the Nervous Tissue
Liao, H., Klaus, C., & Neumann, H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155494 · Cited by 46
P2X7 receptor blockade reduces tau induced toxicity, therapeutic implications in tauopathies
Lauro, C. D., Bianchi, C., Sebastián‐Serrano, Á., Soria-Tobar, L., Alvarez‐Castelao, B., Nicke, A., & Díaz-Hernández, M. (2021) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2021.102173 · Cited by 48
Regulated cell death and its role in Alzheimer’s disease and amyotrophic lateral sclerosis
Thal, D. R., Gawor, K., & Moonen, S. (2024) · Acta Neuropathologica · doi:10.1007/s00401-024-02722-0 · Cited by 50
Tang, Q., Wang, F., Yang, J., Peng, H., Li, Y., Li, B., & Wang, S. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00370 · Cited by 49
Innate Immunity and Cell Death in Alzheimer’s Disease
Lee, S., Cho, H., & Ryu, J. (2021) · ASN NEURO · doi:10.1177/17590914211051908 · Cited by 44
Qiu, T., Wu, C., Yao, X., Han, Q., Wang, N., Yuan, W., Zhang, J., Shi, Y., Jiang, L., Liu, X., et al. (2022) · Cell Biology and Toxicology · doi:10.1007/s10565-022-09703-7 · Cited by 45
The multifaceted role of WNT signaling in Alzheimer’s disease onset and age-related progression.
Kostes, W. W., & Brafman, D. A. (2023) · Cells · doi:10.3390/cells12081204 · Cited by 43
Novel Targets for Alzheimer's Disease: A View Beyond Amyloid
Ray, W. J., & Buggia-Prévot, V. (2020) · Annual Review of Medicine · doi:10.1146/annurev-med-052919-120219 · Cited by 47
Gamma subunit of complement component 8 is a neuroinflammation inhibitor
Kim, J., Afridi, R., Han, J., Jung, H., Kim, S.-C., Hwang, E. M., Shim, H. S., Ryu, H., Choe, Y., Hoe, H., et al. (2020) · Brain · doi:10.1093/brain/awaa425 · Cited by 45
Electroacupuncture Inhibits NLRP3 Activation by Regulating CMPK2 After Spinal Cord Injury
Chen, Y., Wu, L., Shi, M., Zeng, D., Hu, R., Wu, X., Han, S., He, K., Xu, H., Shao, X., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.788556 · Cited by 48
Xu, Y., Lin, F., Liao, G., Sun, J., Chen, W., & Zhang, L. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-03981-4 · Cited by 47
Detrimental Roles of Hypoxia-Inducible Factor-1α in Severe Hypoxic Brain Diseases
Choi, Y. K. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084465 · Cited by 45
Ghosh, P., Singh, R. B., Ganeshpurkar, A., Pokle, A. V., Singh, R. B., Singh, S. K., & Kumar, A. (2021) · Neurochemistry International · doi:10.1016/j.neuint.2021.105212 · Cited by 44
Flores, J., Fillion, M.-L., & LeBlanc, A. C. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05290-x · Cited by 44
Canonical and non-canonical functions of NLRP3
Accogli, T., Hibos, C., & Végran, F. (2023) · Journal of Advanced Research · doi:10.1016/j.jare.2023.01.001 · Cited by 45
Singh, P., Kumar, N., Singh, M., Kaur, M., Singh, G., Narang, A., Kanwal, A., Sharma, K., Singh, B., Napoli, M. D., et al. (2023) · Vaccines · doi:10.3390/vaccines11020261 · Cited by 44
ASC specks exacerbate α‑synuclein pathology via amplifying NLRP3 inflammasome activities
Zheng, R., Yan, Y., Dai, S., Ruan, Y., Chen, Y., Hu, C., Lin, Z., Xue, N., Song, Z., Liu, Y. F., et al. (2023) · Journal of Neuroinflammation · doi:10.1186/s12974-023-02709-w · Cited by 50
Liu, H., Lv, R., Song, F., Yang, Y., Zhang, F., Xin, L., Zhang, P., Zhang, Q., & Ding, C. (2024) · Chemical Science · doi:10.1039/d4sc00595c · Cited by 43
Alzheimer's disease neuropathology and its estimation with fluid and imaging biomarkers
Thal, D. R., Poesen, K., Vandenberghe, R. R., & Meyer, S. D. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00819-y · Cited by 55
Neuroinflammation in Prion Disease
Li, B., Chen, M., & Zhu, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22042196 · Cited by 51
NLRP3 and Infections: β-Amyloid in Inflammasome beyond Neurodegeneration
Sita, G., Graziosi, A., Hrelia, P., & Morroni, F. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22136984 · Cited by 43
Zhang, Q., Zhao, W., Hou, Y., Song, X., Yu, H., Tan, J., Zhou, Y., & Zhang, H. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14132 · Cited by 40
Duan, M., Liu, F., Fu, H., Lu, S., & Wang, T. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.592842 · Cited by 41
Mitochondrial DNA and Inflammation in Alzheimer’s Disease
Galizzi, G., & Carlo, M. D. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45110540 · Cited by 43
Inflammasomes in neurodegenerative diseases
Wang, Q., Yang, S., Zhang, X., Zhang, S., Chen, L., Wang, W., Chen, N., & Yan, J. (2024) · Translational Neurodegeneration · doi:10.1186/s40035-024-00459-0 · Cited by 47
Self-citationGlial cells and adaptive immunity in frontotemporal dementia with tau pathology
Hartnell, I. J., Blum, D. L., Nicoll, J. A. R., Dorothée, G., & Boche, D. (2020) · Brain · doi:10.1093/brain/awaa457 · Cited by 41
Self-citationFinze, A., Biechele, G., Rauchmann, B.-S., Franzmeier, N., Palleis, C., Katzdobler, S., Weidinger, E., Guersel, S., Schuster, S., Harris, S., et al. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02188-8 · Cited by 40
Deubiquitinases in Neurodegeneration
Bello, A. I., Goswami, R., Brown, S. L., Costanzo, K. M., Shores, T., Allan, S. K., Odah, R., & Mohan, R. D. (2022) · Cells · doi:10.3390/cells11030556 · Cited by 42
SARS-CoV-2 infection increases the gene expression profile for Alzheimer’s disease risk
Green, R. J., Mayilsamy, K., McGill, A. R., Martinez, T. E., Chandran, B., Blair, L. J., Bickford, P. C., Mohapatra, S. S., & Mohapatra, S. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.09.007 · Cited by 42
Brain targeting based nanocarriers loaded with resveratrol in Alzheimer's disease: A review
Jalili, C., Kiani, A., Gholami, M., Bahrehmand, F., Fakhri, S., Kakehbaraei, S., & Kakebaraei, S. (2023) · IET Nanobiotechnology · doi:10.1049/nbt2.12127 · Cited by 43
Afsar, A., Castro, M. D. C. C., Soladogun, A. S., & Li, Z. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087258 · Cited by 45
Galectin-3 aggravates microglial activation and tau transmission in tauopathy
Siew, J. J., Chen, H.-M., Chiu, F., Lee, C., Chang, Y., Chen, H.-L., Nguyen, T. N. A., Liao, H.-T., Liu, M., Hagar, H. C., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci165523 · Cited by 47
Self-citationMolecular actions of NLR immune receptors in plants and animals
Wang, J., & Chai, J. (2020) · Science China Life Sciences · doi:10.1007/s11427-019-1687-6 · Cited by 40
Laval, K., & Enquist, L. W. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.658695 · Cited by 43
Yue, F., Feng, S., Lu, C., Zhang, T., Tao, G., Liu, J., Yue, C., & Jing, N. (2021) · iScience · doi:10.1016/j.isci.2021.103207 · Cited by 41
Kai-Xin-San Inhibits Tau Pathology and Neuronal Apoptosis in Aged SAMP8 Mice
Jiao, Y.-N., Zhang, J., Wen-jun, Q., Tian, S.-Y., Wang, Y.-B., Wang, C., Zhang, Y., Zhang, Q., Li, W., Min, D., et al. (2022) · Molecular Neurobiology · doi:10.1007/s12035-021-02626-0 · Cited by 41
Li, D., Fan, H., Yang, R., Li, Y., Zhang, F., & Shi, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.846541 · Cited by 41
Liu, N., Liang, X., Chen, Y., & Xie, L. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102199 · Cited by 44
NLRP3 inflammasome in Alzheimer’s disease: molecular mechanisms and emerging therapies
Li, Z., & Gong, C. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1583886 · Cited by 53
Urkon, M., Ferencz, E., Szász, J. A., Szabó, M. I. M., Orbán-Kis, K., Szatmári, S., & Nagy, E. E. (2025) · Pharmaceuticals · doi:10.3390/ph18050614 · Cited by 43
Vascular Dementia: From Pathophysiology to Therapeutic Frontiers
Yang, H. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14186611 · Cited by 48
The Dichotomous Role of Inflammation in the CNS: A Mitochondrial Point of View
Vezzani, B., Carinci, M., Patergnani, S., Pasquin, M., Guarino, A., Aziz, N., Pinton, P., Simonato, M., & Giorgi, C. (2020) · Biomolecules · doi:10.3390/biom10101437 · Cited by 40
Cerebral sterile inflammation in neurodegenerative diseases
Otani, K., & Shichita, T. (2020) · Inflammation and Regeneration · doi:10.1186/s41232-020-00137-4 · Cited by 39
de Andrade, E. G., Šimončičová, E., Carrier, M., Vecchiarelli, H. A., Robert, M.-È., & Tremblay, M. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.647378 · Cited by 39
Critical Molecular and Cellular Contributors to Tau Pathology
Song, L., Wells, E. A., & Robinson, A. S. (2021) · Biomedicines · doi:10.3390/biomedicines9020190 · Cited by 40
Shao, L., Dong, C., Geng, D., He, Q., & Shi, Y. (2022) · Metabolic Brain Disease · doi:10.1007/s11011-021-00886-2 · Cited by 39
Klotho an Autophagy Stimulator as a Potential Therapeutic Target for Alzheimer’s Disease: A Review
Fung, T., Iyaswamy, A., Sreenivasmurthy, S. G., Krishnamoorthi, S., Guan, X.-J., Zhu, Z., Su, C.-F., Liu, J., Kan, Y., Zhang, Y., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10030705 · Cited by 43
Kumar, S., Budhathoki, S., Oliveira, C. B., Kahle, A. D., Calhan, O. Y., Lukens, J. R., & Deppmann, C. D. (2023) · JCI Insight · doi:10.1172/jci.insight.157433 · Cited by 41
Synapses, Microglia, and Lipids in Alzheimer’s Disease
Paasila, P. J., Aramideh, J. A., Sutherland, G. T., & Graeber, M. B. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.778822 · Cited by 40
Neurodegenerative Microbially-Shaped Diseases: Oxidative Stress Meets Neuroinflammation
Silva, D. F., Empadinhas, N., Cardoso, S. M., & Esteves, A. R. (2022) · Antioxidants · doi:10.3390/antiox11112141 · Cited by 44
Role of mesenchymal stem cell-derived exosomes in the regeneration of different tissues
Huang, D., Shen, H., Xie, F., Hu, D., Jin, Q., Hu, Y., & Zhong, T. (2024) · Journal of Biological Engineering · doi:10.1186/s13036-024-00431-6 · Cited by 43
The anti-inflammatory effects of itaconate and its derivatives in neurological disorders
Kong, X., Xu, L., Mou, Z., Lyu, W., Shan, K., Wang, L., Liu, F., Rong, F., Li, J., & Wei, P. (2024) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2024.07.001 · Cited by 38
Systemic inflammation as a central player in the initiation and development of Alzheimer’s disease
Bayraktaroğlu, I., Ortí-Casañ, N., Dam, D. V., Deyn, P. P. D., & Eisel, U. L. M. (2025) · Immunity & Ageing · doi:10.1186/s12979-025-00529-5 · Cited by 49
Hydrogen Sulfide Plays an Important Role by Influencing NLRP3 inflammasome
Wang, H., Shi, X., Qiu, M., Lv, S., Zheng, H., Niu, B., & Liu, H. (2020) · International Journal of Biological Sciences · doi:10.7150/ijbs.47595 · Cited by 40
Calderón‐Garcidueñas, L., Torres‐Jardón, R., Franco-Lira, M., Kulesza, R. J., González-Maciel, A., Reynoso-Robles, R., Brito-Aguilar, R., García-Arreola, B., Revueltas-Ficachi, P., Barrera-Velázquez, J. A., et al. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200891 · Cited by 40
Modulation of cGAS-STING Pathway by Nicotinamide Riboside in Alzheimer's Disease
Larrick, J. W., & Mendelsohn, A. R. (2021) · Rejuvenation Research · doi:10.1089/rej.2021.0062 · Cited by 39
Impact of zinc on DNA integrity and age-related inflammation
Ho, E., Wong, C. P., & King, J. C. (2021) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2021.12.256 · Cited by 40
Physiological and pathophysiological functions of NLRP6: pro- and anti-inflammatory roles
Angosto-Bazarra, D., Molina‐López, C., & Pelegrín, P. (2022) · Communications Biology · doi:10.1038/s42003-022-03491-w · Cited by 38
Research Progress of Pyroptosis in Alzheimer’s Disease
Xue, W., Cui, D., & Qiu, Y. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.872471 · Cited by 37
Prospective Role of Polyphenolic Compounds in the Treatment of Neurodegenerative Diseases
Akter, R., Rahman, H., Behl, T., Chowdhury, M. A. R., Manirujjaman, M., Bulbul, I. J., Elshenawy, S. E., Ţiţ, D. M., & BUNGAU, S. G. (2021) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527320666210218084444 · Cited by 40
Liao, Y., Wang, X., Huang, L., Qian, H., & Liu, W. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1122104 · Cited by 37
Neurotoxicity of Micro- and Nanoplastics: A Comprehensive Review of Central Nervous System Impacts
Ma, Q., Lei, J., Pang, Y., Yu, S., & Zhang, T. (2025) · Environment & Health · doi:10.1021/envhealth.5c00087 · Cited by 43
Lago, N., Kaufmann, F. N., Negro‐Demontel, M. L., Alí‐Ruiz, D., Ghisleni, G., Rego, N., Arcas-García, A., Vitureira, N., Jansen, K., Souza, L. M., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1911816117 · Cited by 38
Metadata
- Authors
- Ising, C., Venegas, C., Zhang, S., Scheiblich, H., Schmidt, S. V., Vieira-Saecker, A., Schwartz, S., Albasset, S., McManus, R. M., Tejera, D., Griep, A., Santarelli, F., Brosseron, F., Opitz, S., Stunden, J., Merten, M., Kayed, R., Golenbock, D. T., Blum, D., Latz, E., Buée, L., & Heneka, M. T.
- Affiliations
- University Hospital Bonn (DE)
- German Center for Neurodegenerative Diseases (DE)
- The University of Texas Medical Branch at Galveston (US)
- University of Massachusetts Chan Medical School (US)
- Inserm (FR)
- Corresponding author
- Heneka, Michael T.
- ORCID
- Venue
- Nature
- Published
- 2019-11-20
- Volume
- 575
- Issue
- 7784
- Pages
- 669-673
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC7324015
- OpenAlex
- W2990312754
- Semantic Scholar
- 6a9d745a33a2d013c621f57586d9d719671530a7
- Cited by
- 1,487
- References
- 28
- Citations by year
- 2026: 189 · 2025: 226 · 2024: 255 · 2023: 226 · 2022: 248 · 2021: 193 · 2020: 143 · 2019: 3
- FWCI
- 101.29
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Open Repository and Bibliography (University of Luxembourg) (submittedVersion, other-oa)
- HAL (submittedVersion, other-oa)
- RePEc: Research Papers in Economics (submittedVersion)
- Institutional Repository of the University of Granada (University of Granada) (submittedVersion, cc-by-nc-nd)
- DZNE Pub (submittedVersion)
- Funders
- Deutsche Forschungsgemeinschaft (R01 AG059752-02)
- Agence Nationale de la Recherche (ANR-11-LABX-0009)
- Deutsches Zentrum für Neurodegenerative Erkrankungen
- National Institutes of Health
- National Institute on Aging (R01AG059752, R01AG054025)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- NLRP3 inflammasome, tau hyperphosphorylation, tau aggregation, neurofibrillary tangles, Alzheimer's disease, amyloid-beta, microglia, amyloid hypothesis, frontotemporal dementia, neuroinflammation, caspase-1, IL-1β
- MeSH terms
- NLR Family, Pyrin Domain-Containing 3 Protein, Animals, Gene Expression Regulation, Humans, Mice, Inbred C57BL, Phosphorylation, tau Proteins, Microglia, Cyclin-Dependent Kinase 5, Mice, Inflammasomes, Protein Aggregation, Pathological
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
